Compare Amphastar Pharmaceuticals Inc (AMPH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while State Street SPDR S&P Biotech ETF trades at $158.19. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XBI | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $164.28 |
52-Week Low | $16.87 | $86.92 |
Enterprise Value | $1.27B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
